News

not found

Uzbekistan’s Medicine Price Optimization Policy Recognized with an International Award

Reforms in Uzbekistan aimed at expanding access to high-quality, safe, and affordable medicines have been recognized by the international pharmaceutical community. The project of the Agency for the Development of the Medical and Pharmaceutical Industry, “Making Medicines Affordable in Uzbekistan: Reference Pricing, Digital Monitoring and Public Access,” aimed at optimizing medicine prices, establishing reference prices, digitalizing price monitoring, and providing the public with transparent information, was named the winner in the “Excellence With Purpose” category of the “CPHI Pharma Awards 2026” international awards. Announced on October 6 this year in Milan, this result represents international recognition of the systemic reforms being implemented in Uzbekistan in the interests of the population. As part of the project, mechanisms for establishing reference prices for medicines, regularly analyzing and digitally monitoring prices, as well as providing the public with open and accessible information on medicine prices, are being improved. The main objective of the reference pricing system is to prevent unjustified increases in medicine prices, ensure fair price formation in the market, and create opportunities for people to purchase medicines at more affordable prices. The “CPHI Pharma Awards” recognize initiatives in the pharmaceutical sector that demonstrate innovation, effectiveness, collaboration, and social impact. The “Excellence With Purpose” category recognizes projects focused on the interests of patients and society and delivering positive social impact. The recognition of Uzbekistan’s project as the winner in this category demonstrates that the country’s efforts to optimize medicine prices, ensure transparency, and introduce digital control mechanisms have attracted the attention of the international professional community. This is an important international recognition for Uzbekistan’s pharmaceutical system and will provide additional momentum for the consistent continuation of reforms focused on the interests of the population.

  • 7 October, 13:04
  • Read more
not found

Cancer cases expected to soar worldwide, WHO report finds

One person in five will develop cancer, according to WHO estimates, and the disease will touch 92% of people, either through their own diagnosis or that of a close family member. Remarkable scientific progress against cancer has changed very little for millions of patients globally, who face devastating physical, emotional and financial consequences after diagnosis, a new World Health Organization report has warned. This year’s WHO global status report on cancer found “persistent and widening” inequities in access to prevention, diagnosis, treatment and care. There are an estimated 20.6m cases, and 10m deaths, from cancer every year. Figures are projected to rise to nearly 35m cases by 2050. In richer countries, 85% of those diagnosed with breast or childhood cancers will survive at least five years but the figure drops to less than 30% in poorer countries. In low- and lower-middle income countries, between 9% and 54% of the WHO’s top-20 priority cancer drugs are available, compared with between 68% and 94% in high-income countries, the report found. In 23 countries there are no radiation facilities. Two-thirds of countries do not cover cancer in universal health coverage packages, and high costs mean up to 90% of patients in some settings abandon treatment, the report said. A global survey of patients and their families found widespread financial hardship, mental health challenges and strain on caregivers. The report also highlights successes including a credible path to elimination of cervical cancer, and a downward trend in tobacco use. Most countries now have national cancer action plans. Dr Isabelle Soerjomataram, deputy head of the International Agency for Research on Cancer’s surveillance unit, which worked with the WHO on the report, said a further positive message was that “four in 10 new cancer cases are linked to risk factors which we already know how to address. This includes tobacco use, infections, alcohol use and excess body weight.” The WHO experts called on the global community to “value care as highly as cure”, and on governments to fund cancer services from prevention to diagnosis to treatment.

  • 13 July, 09:39
  • Read more
not found

Important agreements in pharmaceuticals and biotechnology reached within the framework of the Uzbekistan–Korea Business Forum

Within the framework of the “5th Tashkent International Investment Forum,” Director of the Agency for the Development of the Medical and Pharmaceutical Industry Abdulla Azizov and agency representatives actively participated in the Uzbekistan–Korea Business Forum. During the forum, participants discussed cooperation in infrastructure, investment, innovation, industry, and high technologies. Promising areas of cooperation in the development of the pharmaceutical industry, introduction of modern medical technologies, implementation of investment projects, and enhancement of human capital were also reviewed. As part of the event, a Cooperation Agreement on the establishment of the innovative biotechnology cluster “SMART-BIO CLUSTER” was signed between the Ministry of Investments, Industry and Trade, the Agency for the Development of the Medical and Pharmaceutical Industry, and the Republic of Korea’s Korea Overseas Infrastructure & Urban Development Corporation (KIND). In addition, a Memorandum of Understanding was signed with South Korea’s "Kim & Kim" company aimed at legal support in the biopharmaceutical sector, improvement of the regulatory framework, and exchange of experience. Within the framework of the forum, B2B and G2B meetings were held to discuss attracting investments into the pharmaceutical sector, introducing innovative developments, expanding local production, and implementing new joint projects. The signed agreements will contribute to the development of innovative biotechnology and the pharmaceutical industry in Uzbekistan, the establishment of high value-added production facilities, the strengthening of research capacity, and the advancement of practical cooperation between the Republic of Uzbekistan and the Republic of Korea to a new level.

  • 17 June, 09:20
  • Read more
Нажмите на кнопку ниже, чтобы прослушать текст Powered by GSpeech